Valid: August 31st, 2009 - August 31st, 2010
This activity is no longer available for credit, however its content is still relevant for your educational needs.
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma (MM).
This activity was developed for physicians, nurses, and pharmacists.
At the completion of this activity participants should be able to:
- Explain how various agents and combination regimens used in induction regimens for multiple myeloma (MM) may affect stem cell mobilization
- Describe the safety and efficacy of standard agents used for stem cell mobilization in patients withMM
- Interpret data from clinical trials evaluating novel approaches to stem cell mobilization as reported at the 2008 ASH meeting
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakersâ€™ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner
|Amanda Glazar, PhD||Global||Nothing to disclose|
|Hao Vu, RPh||MLI||Nothing to disclose|
|Ryan Sims, CRNA, MS||MLI||Nothing to disclose|
|Karen Cooksey||COEXM||Nothing to disclose|
|Susan Berry||COEXM||Nothing to disclose|
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.
William Bensinger, MD, is on the speaker's bureau for Celgene, is a consultant to Millennium, and has received research grants from AstraZeneca, Celgene, Genzyme, Geron, Millennium, and Onyx.
Beth Faiman, RN, MSN, APRN, BC, AOCN is on the speaker's bureau for Millennium and Celgene.
Helen Leather, BPharm, BCPS is a consultant for Genzyme and Novartis.
*Content will include non-FDA-approved uses.
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.